Loading…
Please register to continue your trial period!
meRfi-GM provides you with up-to-date, evidence-based insights on the gut microbiota and related health topics.
Access our ever-expanding digital library and get personalized answers through our interactive AI chat platform.
Start your free trial and transform your understanding of the gut microbiota today!
In the context of Large B-cell lymphoma (LBCL) / Diffuse Large B-Cell Lymphoma (DLBCL) , diffuse Large B-cell Lymphoma (DLBCL) is the most common subtype of Non-Hodgkin Lymphoma, with the majority of patients (pts) achieving long-term survival due to the curative nature of frontline therapy.
Diffuse large B-cell lymphoma comprises a heterogenous group of morphologically, genetically, and clinically distinct diseases.
Diffuse large B-cell lymphoma (DLBCL) is the most common aggressive lymphoma.
Relapsed or refractory diffuse large B-cell lymphoma (DLBCL) has a poor prognosis.
Epidemiological studies have established th…